Joan Genescà

Prof. Joan Genescà

Hospital Universitario Vall d´Hebrón, Barcelona, Catalonia, Spain
orcid

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 1989 in The Lancet
Verified
Journal Article
Closed access
JEJ.I. Esteban
J.I. Esteban
LVL. Viladomiu
L. Viladomiu
AGA. Gonzalez
A. Gonzalez
MRM. Roget
M. Roget
JGJoan Genescà
Joan Genescà
GKG. Kuo
G. Kuo

1 April 2020 in Journal of Hepatology
Verified
Journal Article
Closed access
RMRichard Moreau
Richard Moreau
JCJoan Clària
Joan Clària
FAFerran Aguilar
Ferran Aguilar
FFFrançois Fenaille
François Fenaille
JLJuan Jose Lozano
Juan Jose Lozano
PAPaolo Angeli
Paolo Angeli

27 October 2016 in Hepatology
Verified
Journal Article
Closed access
PDF file
JAJuan G. Abraldes
Juan G. Abraldes
CBChristophe Bureau
Christophe Bureau
HSHoria Stefanescu
Horia Stefanescu
SASalvador Augustin
Salvador Augustin
MNMichael Ney
Michael Ney
FIfor the Anticipate Investigators
for the Anticipate Investigators

1 February 2014 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
EREnric Reverter
Enric Reverter
PTPuneeta Tandon
Puneeta Tandon
SASalvador Augustin
Salvador Augustin
FTFanny Turon
Fanny Turon
SCStefania Casu
Stefania Casu
JAJuan G. Abraldes
Juan G. Abraldes

6 March 2017 in Hepatology
Verified
Journal Article
Open access
PDF file
ABAnnalisa Berzigotti
Annalisa Berzigotti
AAAgustín Albillos
Agustín Albillos
CVCandid Villanueva
Candid Villanueva
JGJoan Genescà
Joan Genescà
AAAlba Ardevol
Alba Ardevol
OGon behalf of the Ciberehd SportDiet Collaborative Group
on behalf of the Ciberehd SportDiet Collaborative Group
Obesity increases the risk of clinical decompensation in cirrhosis, possibly by increasing portal pressure. Whether weight reduction can be safely achieved through lifestyle (LS) changes (diet and exercise) in overweight/obese patients with cirrhosis, and if weight loss reduces portal pressure in this setting, is unknown. This prospective, multicentric, uncontrolled pilot study enrolled patients with compensated cirrhosis, portal hypertension (hepatic venous pressure gradient [HVPG] ≥6 mm Hg), and body mass index (BMI) ≥26 kg/m2 in an intensive 16‐week LS intervention program (personalized hypocaloric normoproteic diet and 60 min/wk of supervised physical activity). We measured HVPG, body weight (BW) and composition, adipokines, health‐related quality of life, and safety data before and after the intervention. Changes in HVPG and BW were predefined as clinically relevant if ≥10% and ≥5%, respectively. Safety and BW were reassessed after 6 months. 60 patients were included and 50 completed the study (56 ± 8 years old; 62% male; nonalcoholic steatohepatitis etiology 24%; BMI 33.3 ± 3.2 kg/m2; Child A 92%; HVPG ≥10 mm Hg, 72%). LS intervention significantly decreased BW (average, –5.0 ± 4.0 kg; P < 0.0001), by ≥5% in 52% and ≥10% in 16%. HVPG also significantly decreased (from 13.9 ± 5.6 to 12.3 ± 5.2 mm Hg; P < 0.0001), by ≥10% in 42% and ≥20% in 24%. A ≥10% BW loss was associated with a greater decrease in HVPG (–23.7 ± 19.9% vs. –8.2 ± 16.6%; P = 0.024). No episodes of clinical decompensation occurred. Weight loss achieved at 16 weeks was maintained at 6 months; Child and Model for End‐Stage Liver Disease scores did not change. Conclusion: Sixteen weeks of diet and moderate exercise were safe and reduced BW and portal pressure in overweight/obese patients with cirrhosis and portal hypertension. (Hepatology 2017;65:1293‐1305).

1 May 2016 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
JAJuan G. Abraldes
Juan G. Abraldes
CVCandid Villanueva
Candid Villanueva
CACarles Aracil
Carles Aracil
JTJuan Turnes
Juan Turnes
MHManuel Hernández-Guerra
Manuel Hernández-Guerra
NRNúria Ramos
Núria Ramos